Additionally, an analysis of IL-26 serum levels in 302 GC patients across various stages (I, II, III, and IV) demonstrated that IL-26 levels were significantly higher in patients with malignant tumors compared to those with benign conditions. This evidence concerns the gene IL26 and cancer.